Available Projects

Standard_2026_09: Towards Predictive Models of Glioblastoma Recurrence: Bridging Experimental Biology and Computational Oncology (Dr Kevin Critchley) Standard_2026_25: Save Our Souls: Allosteric inhibitors of Sos for targeting Ras-driven cancers using fragment-based drug discovery with structure-driven medicinal chemistry (Prof Alex Breeze) Standard_2026_26: Bio-inspired probes for rapid, sensitive and accurate detection of bacterial infection (Prof Yuan Guo) Standard_2026_39: Determining how alterations to leg vasculature and skeletal muscle in diabetes and peripheral arterial disease lead to the need for amputation (Prof Michelle Peckham) Standard_2026_42: Next-Ge n Molecular Tools: AI-driven cyclic peptides to target cancer (Prof Darren Tomlinson) Standard_2026_50: Zoonotic transmission dynamics of influenza A virus at the swine-human interface (Dr James Rudge) Standard_2026_82: You are only as old as your arteries – how targeting BACE1 in blood vessels could be the key to healthy aging (Dr Paul Meakin) Standard_2026_117 Development of chemical probes and drug leads for the treatment of recurrent, therapy-resistant brain cancer (Prof Robin Bon) Standard_2026_127: Using cryoEM and the transplantation of human microglia in the mouse brain to decode microglial dysfunction in Parkinson’s Disease (Dr Marine Krzisch) Standard_2026_146: Targeting Therapy-Resistant Leukaemic Stem Cells in Acute Myeloid Leukaemia. (Dr Anjum Khan) Standard_2026_153: Pathophysiological investigations of misfolded Alpha Synuclein in Human Brain Slice Cultures (Dr Jessica Kwok) Standard_2026_159: Towards novel antivirals targeting the assembly of viral factories (Dr Antonio Calabrese) Standard_2026_162: Uncovering how natural killer and cancer cells interact using structural cell biology (Dr Helen Foster) Standard_2026_163: Predicting cancer response to radiotherapy through the discovery of novel biomarkers. (Dr Chiara Gorrini) Standard_2026_189: Quantitative analysis of hepatitis E virus proteolysis (Dr Morgan Herod) Standard_2026_193: Role of dysregulated micropeptides in lymphoproliferative diseases (Prof Adrian Whitehouse) Standard_2026_203: Making small molecules isoform selective through conjugation (Prof Michael Webb) iCASE_2026_26: Neural Extracellular Matrix Modulation to Improve Frailty in Ageing ( Dr Richard Foster and iCASE partner Cintralis Ltd) iCASE_2026_02: Plugging the holes in pandemic coronavirus therapy (Prof Stephen Griffin and iCASE partner Sophion Bioscience)

iCASE_2026_03: Solving the problem of chemotherapy-induced lung injury to improve cancer patient safety (Prof Dan Carr and iCASE partner AstraZeneca) iCASE_2026_04: Solving safety issues in cancer patients receiving kinase inhibitors and immunotherapy ( Prof Dean Naisbitt and iCASE partner AstraZeneca) iCASE_2026_09: Unlocking the Role of Annexin A1 in Pancreatic Cancer Metastasis: A New Avenue for Therapy (Prof Ainhoa Mielgo and iCASE partner Medannex) iCASE_2026_16: Decoding RNA Signatures: Novel Biomarkers and Mechanisms of Cancer Therapy-Associated Organ Injury (Dr Aditi Kanhere and iCASE partner TAmiRNA) iCASE_2026_17: Towards Mitigating Severe Neurotoxicity in T-cell Immunotherapy (Dr David Dickens and iCASE partner AstraZeneca) iCASE_2026_18: Synthetic Teixobactins: Tackling Drug-Resistant Pneumonia Caused by S. pneumoniae and S. aureus (Dr Ishwar Singh and iCASE partner Bachem (UK) Ltd) iCASE_2026_19: Goldilocks and Chemotherapy Resistance: Resolving Mixed Outcomes in Pyrimidine-Based Treatment of Cancer (Prof William Greenhalf and iCASE partner NuCana plc) iCASE_2026_20: Laser Interstitial Thermal Therapy for lesional epilepsy: clinical, surgical and imaging predictors of seizure control, quality of life and comorbidities (Prof Simon Keller and iCASE partner Medtronic) iCASE_2026_25: Understanding TRIB2 syndrome: A neurodevelopmental disorder caused by abnormal TRIB2 proteostasis (Prof Patrick Eyers and iCASE partner Sulantrix Ltd) Standard_2026_07: Immune Failure in Pancreatic Cancer Metastasis (Prof Michael Schmid) Standard_2026_37 Improving success of mandibular reconstruction after oral cancer: novel finite element methods for better patient outcomes (Dr Alana Sharp) Standard_2026_53: Advancing Cancer Care: From Mechanistic Insights to Point-of-Care Solutions (Prof David Wright) Standard_2026_54: Personalising Cancer Care: A Multiplex Biosensor for Real-Time Cardiotoxicity Risk Assessment in Chemotherapy (Prof Reecha Sofat) Standard_2026_61: Towards pandemic preparedness: Identifying barriers for interspecies transmission of influenza A virus (Dr Mahmoud Naguib) Standard_2026_72: Metabolic Reprogramming of the Cholangiocarcinoma Immune Microenvironment using Mitochondrial Uncouplers as Metabolic Adjuvants for CAR-T/NK Cell Therapies (Prof Neill Liptrott) Standard_2026_93: From Meiotic Genes to Cancer Immunotherapy: Overcoming Radiotherapy Resistance in Liver Cancer (Dr Urszula McClurg) Standard_2026_97: Repurposing Anti-Diabetic Drugs for Neurodegenerative and Psychiatric Disorders: A Translational Data Science Approach (Dr Vicky Garfield) Standard_2026_113: Uncovering the molecular mechanisms underpinning A. baumannii virulence (Dr Christopher Harding) Standard_2026_116: Investigating the impact of pre-existing adenovirus immunity on the safety and efficacy of adenoviral-based vaccines and therapeutics (Dr Joshua Gardner) Standard_2026_129: How does Wnt and Notch (Wntch) signalling coordinate cell fate assignment during gastrulation? (Dr David Turner) Standard_2026_155: MitoFit: safeguarding mitochondrial health in the aging brain (Prof Sylvie Urbé) Standard_2026_171: From model to medicine: In ovo organoid xenografts to accelerate gastric cancer drug and biomarker development (Dr Carrie Duckworth) Standard_2026_173: Defining the Function and Therapeutic Potential of a Deubiquitylase in cancer related pathways. (Prof Michael Clague) Standard_2026_188: Resistant zombies: how drug-resistance plasmids manipulate the behaviour of the opportunistic pathogen Pseudomonas aeruginosa (Dr James Hall) Standard_2026_200: Stopping premature ageing: Investigating a nuclear rheostat for cellular actomyosin tension (Prof Tobias Zech) Standard_2026_204: The intersection of mechanical signalling and the hypoxic response as a targetable signalling nexus in pancreatic cancer. (Prof Ben Goult) Standard_2026_231: A structural biology approach to understand IMPDH2 rod-ring structures in Embryonic Stem Cells (Prof Dan Rigden)

Standard_2026_16: Hiding in plain sight: How a multi-drug resistant pathogen evades detection and killing by human neutrophils (Dr James Connolly) Standard_2026_30: Fuelling the Fight: Novel Discoveries in Fatty Acid Metabolism for Parkinson’s Neuroprotection. (Dr Chun Chen) Standard_2026_31: The role of Innate Immunity in Mitochondrial Disease (Prof Gavin Hudson) Standard_2026_35: Targeting thioredoxin reductase to combat antifungal resistance in Candida spp. (Dr Alessandra da Silva Dantas) Standard_2026_36: Re-sensitisation of antibiotic-tolerant Staphylococcus aureus small colony variants (Prof Henrik Strahl) Standard_2026_56: Unexpected role of RNA polymerase in development of Methicillin resistance in S. aureus (MRSA). (Prof Nikolay Zenkin) Standard_2026_65: Vision and Sensory Processing in Autism: Linking Lived Experience with Retinal Development (Dr Rachel Queen) Standard_2026_83: Molecular mechanism of slow growth and antibiotic tolerance in Mycobacterium tuberculosis using single-molecule microscopy (Dr Kevin Whitley) Standard_2026_84: Structural and Functional Analysis of Drug Resistance in Tuberculosis via a Novel MmpL3 Binding Site. (Dr Alistair K Brown) Standard_2026_85: Molecular profiling of selenoprotein genes in breast, ovarian, uterine, and cervical cancers (Dr Catherine Meplan) Standard_2026_107: Unravelling, and therapeutically targeting, the mechanisms of treatment resistance in relapsed medulloblastoma. (Dr Rebecca Hill) Standard_2026_144: Targeting oncogene-induced replication stress in squamous cell carcinoma (Dr Ute Jungwirth) Standard_2026_156: Multiomic profiling of Fumarate Hydratase deficient leiomyomas to discover novel therapeutic vulnerabilities. (Prof Neil Rajan) Standard_2026_158: Global Pathogen, Local Impact: Genomic and Functional Dissection of S. Infantis in Peru ( Dr Matt Bawn) Standard_2026_183: How do cells reset and then recall their transcriptional programme during cell division? (Prof Jonathan Higgins) Standard_2026_197: Transcription in malaria Plasmodium organelles: Mechanisms and Drug Targets (Dr Yulia Yuzenkova) Standard_2026_198: The ageing nucleus in the mammalian oocyte (Dr Suzanne Madgwick) Standard_2026_213: Enabling sensitive retinal biomarkers using adaptive optics imaging, simulation and AI (Dr Laura Young) iCASE_2026_12: Harnessing the power of RNA modification to develop new precision therapies for prostate cancer (Prof David Elliott and iCASE partner Nanovery Limited) iCASE_2026_13: Minimally Invasive Skin Microsampling for Early Skin Cancer Detection and Prevention (Dr Keng Wooi Ng and iCASE partner Lynton Lasers Limited) iCASE_2026_05: Engineering Human Synovium-on-a-Chip to Investigate Gut–Joint Inflammation (Dr Priscila Melo and iCASE partner Aelius Biotech)

Standard_2026_11: A search for pharmacological inhibitors of a cancer-associated adhesion GPCR in the zebrafish embryo (Prof Tanya Whitfield) Standard_2026_14: Next-Generation Wound Dressings to Defeat Superbugs: Disrupting Virulence to Combat AMR (Dr Ilida Ortega Asencio) Standard_2026_15: Deconvoluting the spatial multi-omic landscape of high-grade glioma to target post-surgical residual disease (Prof Spencer Collis) Standard_2026_24: Understanding how connexin dysfunction in astrocytes influences disease progression heterogeneity in motor neuron disease (MND) (Dr Matthew Livesey) Standard_2026_29: Getting to the heart of cardiac infection using zebrafish models (Dr Philip Elks) Standard_2026_57: How do type I interferons combat bacterial infection? (Dr Gillian Tomlinson) Standard_2026_66: Personalising Medicine: using Biological Age Profiling to Revolutionise Vaccine Treatment and Boost Immunity (Dr Heather Wilson) Standard_2026_76: Targeting Iron-Laden Macrophages with Therapeutic Nanoparticles to Improve Recovery After Haemorrhagic Stroke (Dr Zahraa Al-Ahmady) Standard_2026_79: Developing Gene Therapy for Charcot-Marie-Tooth Disease using Human Stem Cell Models. (Prof Ivana Barbaric) Standard_2026_80: Exciting PhD opportunity - Cracking the RNA Code of Inflammation: A New Frontier in Ageing Research (Prof Stephen Renshaw) Standard_2026_86: Building a virtual human embryo to predict developmental success and failure (Prof Alexander Fletcher) Standard_2026_100: Combination therapy for cancer: state-of-the art immunotherapy and cold electrical atmospheric plasma for better outcomes (Prof Rob Short) Standard_2026_161: Understanding and Targeting Disease Causing DNA interactions. (Dr Erin Cutts) Standard_2026_174: Breaking the wall to finding new drugs for antimicrobial resistant fungi (Prof Simon Johnston) Standard_2026_205: Doubling down: determining the dual function of VanT in C. difficile antibiotic resistance. (Dr Robert Fagan) Standard_2026_210: How can we target DNA polymerases to fight antimicrobial resistance? (Dr Tim Craggs) Standard_2026_215: A new imaging approach to unravel the mysteries of extracellular vesicle journey through tissues as a vector for cancer proliferation (Prof Julia Weinstein) Standard_2026_232: Understanding the membrane recruitment of oncogenic KRAS in pancreatic cancer (Dr Helen Matthews)

iCASE_2026_06: Photonic detection of Alzheimer’s disease biomarkers: conformational fingerprinting of blood-based proteins (Dr Steven Quinn and iCASE partner Exciting Instruments Limited) iCASE_2026_08: Next-generation magnetoencephalography biomarkers for concussion and brain injury. (Prof Beth Jefferies and iCASE partner Innovision IP Ltd) iCASE_2026_11: Computational Drug Discovery Targeting DNA Gyrase to Tackle Antimicrobial Resistance. (Dr Agnes Noy and iCASE partner Inspiralis Ltd.) Standard_2026_32: Can skin inflammation stop mosquito-borne virus infection? (Dr Clive McKimmie) Standard_2026_33: Enhancing protein therapeutic efficacy via acylation. (Dr Chris Spicer) Standard_2026_40: Harnessing proteostasis to boost blood stem cell expansion for bone marrow transplantation. (Dr William Grey) Standard_2026_62: Targeting GSK3β at the subcellular level - a new approach to tackle dementia. (Dr Ines Hahn) Standard_2026_87: Electrifying Cancer Research: Ionic Signalling and Hypoxia in Blood Cancer (Prof William Brackenbury) Standard_2026_101: Talking Electrically to Cells: Discovering Transmembrane Proteins to Improve Cell – Bioelectronic Interfaces for Electroceuticals and Biosensors. (Dr Stuart Higgins) Standard_2026_125: Fishy Business: How Endogenous Retroviruses drive Brain Autoimmunity in Zebrafish. (Dr Oliver Bayfield) Standard_2026_128: Unravelling Biomolecular Condensate Regulation in Trypanosoma brucei. (Dr Mathieu Cayla) Standard_2026_148: How Bacterial Co-infections Affect Drug Response in a Neglected Tropical Skin Disease (Dr Katrien Van Bocxlaer) Standard_2026_152: Rapid and sensitive diagnostic ‘fingerprinting’ of prostate cancer O-glycans using Fourier-Transform alternative current voltammetry (FTACV). (Prof Alison Parkin) Standard_2026_179: Microbes, Molecules, and Medicine: Unravelling Isotretinoin’s Impact on the Skin Microbiome and Inflammasome Activation in Acne (Dr Kim Samirah Robinson) Standard_2026_219: Discovery of Novel Inhibitors targeting HerpesVirus assembly. (Prof Fred Antson) Standard_2026_229: Masters of adaption: How Leishmania parasites sense and survive in hostile environments. (Dr Nicola Baker) Standard_2026_233: Understanding molecular mechanisms of protein-primed genome replication in enteroviruses (Dr Chris Hill) Standard_2026_234: Dissecting anti-cancer immune responses with long-read RNA Sequencing (Prof Dimitris Lagos).